Brasília – The Director-President of Brazil’s National Health Surveillance Agency (Anvisa), Leandro Pinheiro Safatle, announced that his administration will focus on expanding engagement with state and municipal health bodies, as well as with the Legislative and Judicial branches. His priorities include improving regulatory efficiency, accelerating decision-making, and reinforcing institutional coordination across agencies.

Safatle highlighted plans to address long-standing backlogs in drug registration and product evaluation. He stated that Anvisa will hire additional staff, modernize its infrastructure, introduce artificial intelligence tools, and redesign internal workflows to shorten review times while maintaining scientific rigor.

He also reaffirmed the agency’s central role in Brazil’s health-innovation ecosystem. According to Safatle, regulatory decisions must be closely aligned with the Drug Market Regulation Chamber (CMED), which oversees price evaluations, and the National Commission for the Incorporation of Technologies in the Unified Health System (Conitec), which assesses new technologies for public adoption. These collaborations, he said, are essential to ensure timely access to innovative therapies while preserving fiscal sustainability.

Source: JOTA

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com